Biotage AB (publ)

OM:BIOT Voorraadrapport

Marktkapitalisatie: SEK 14.8b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Biotage Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Biotage is de winst gegroeid met een gemiddeld jaarlijks percentage van 7.2%, terwijl de Life Sciences industrie de winst jaarlijks groeide met 26.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 14.3% per jaar. Het rendement op eigen vermogen van Biotage is 6.6%, en het heeft een nettomarge van 12.1%.

Belangrijke informatie

7.2%

Groei van de winst

4.3%

Groei van de winst per aandeel

Life Sciences Groei van de industrie31.8%
Inkomstengroei14.3%
Rendement op eigen vermogen6.6%
Nettomarge12.1%
Volgende winstupdate23 Oct 2024

Recente prestatie-updates uit het verleden

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Feb 22
Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Recent updates

Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Sep 17
Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Jul 19
Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Jun 08
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

May 21
Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Apr 28
Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Apr 17
Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Apr 08
Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Apr 03
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Mar 04
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Feb 22
Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Feb 21
Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 18
Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Feb 08
Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

Jan 07
Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Dec 08
At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Oct 27
Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Jul 12
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Jun 08
An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

May 24
Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 05
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Mar 12
These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Feb 21
Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Jan 06
Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Dec 03
Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Oct 27
Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Oct 07
Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Biotage (STO:BIOT) Could Easily Take On More Debt

Sep 03
Biotage (STO:BIOT) Could Easily Take On More Debt

Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

Jul 10
Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Jun 25
A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

May 28
Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 23
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Biotage (STO:BIOT) Is Paying Out A Larger Dividend Than Last Year

Mar 29
Biotage (STO:BIOT) Is Paying Out A Larger Dividend Than Last Year

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Mar 14
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Opbrengsten en kosten

Hoe Biotage geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

OM:BIOT Opbrengsten, kosten en inkomsten (SEK Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 242,077251734182
31 Mar 241,981236695174
31 Dec 231,862246636159
30 Sep 231,602189621140
30 Jun 231,554216578125
31 Mar 231,541240546112
31 Dec 221,566268529109
30 Sep 221,524240494107
30 Jun 221,42822846798
31 Mar 221,33721643296
31 Dec 211,23220539691
30 Sep 211,18820337280
30 Jun 211,14518735376
31 Mar 211,09617435573
31 Dec 201,09217537572
30 Sep 201,08314939476
30 Jun 201,10317941779
31 Mar 201,13120141579
31 Dec 191,10118739979
30 Sep 191,04719637577
30 Jun 1999717335272
31 Mar 1995117033970
31 Dec 1891116832466
30 Sep 1886517530959
30 Jun 1881116229260
31 Mar 1877114827556
31 Dec 1774813926256
30 Sep 1773812226253
30 Jun 1772811825952
31 Mar 1769410525352
31 Dec 166689324549
30 Sep 166579623452
30 Jun 166408723051
31 Mar 166257822449
31 Dec 156117322250
30 Sep 155808321447
30 Jun 155497520444
31 Mar 155217519643
31 Dec 144906518738
30 Sep 144745318235
30 Jun 144594917834
31 Mar 144554617834
31 Dec 134454117733

Kwaliteitswinsten: BIOT heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (12.1%) BIOT } zijn lager dan vorig jaar (13.9%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van BIOT is de afgelopen 5 jaar met 7.2% per jaar gegroeid.

Versnelling van de groei: De winstgroei van BIOT over het afgelopen jaar ( 16.2% ) overtreft het 5-jarig gemiddelde ( 7.2% per jaar).

Winst versus industrie: De winstgroei BIOT over het afgelopen jaar ( 16.2% ) overtrof de Life Sciences -sector -13%.


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 6.6% ) van BIOT wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden